Logo image of CVKD

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CVKD - US1276362076 - Common Stock

8.75 USD
+0.08 (+0.92%)
Last: 1/14/2026, 10:02:59 AM
Fundamental Rating

2

Taking everything into account, CVKD scores 2 out of 10 in our fundamental rating. CVKD was compared to 190 industry peers in the Pharmaceuticals industry. The financial health of CVKD is average, but there are quite some concerns on its profitability. CVKD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CVKD has reported negative net income.
  • CVKD had a negative operating cash flow in the past year.
CVKD Yearly Net Income VS EBIT VS OCF VS FCFCVKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of CVKD (-351.94%) is worse than 93.68% of its industry peers.
  • The Return On Equity of CVKD (-525.99%) is worse than 81.05% of its industry peers.
Industry RankSector Rank
ROA -351.94%
ROE -525.99%
ROIC N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CVKD Yearly ROA, ROE, ROICCVKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CVKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVKD Yearly Profit, Operating, Gross MarginsCVKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CVKD has more shares outstanding
  • CVKD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CVKD Yearly Shares OutstandingCVKD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
CVKD Yearly Total Debt VS Total AssetsCVKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • CVKD has an Altman-Z score of -15.35. This is a bad value and indicates that CVKD is not financially healthy and even has some risk of bankruptcy.
  • CVKD has a Altman-Z score of -15.35. This is in the lower half of the industry: CVKD underperforms 78.95% of its industry peers.
  • There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.35
ROIC/WACCN/A
WACCN/A
CVKD Yearly LT Debt VS Equity VS FCFCVKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that CVKD has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.02, CVKD perfoms like the industry average, outperforming 52.11% of the companies in the same industry.
  • A Quick Ratio of 3.02 indicates that CVKD has no problem at all paying its short term obligations.
  • CVKD has a Quick ratio of 3.02. This is comparable to the rest of the industry: CVKD outperforms 55.26% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 3.02
CVKD Yearly Current Assets VS Current LiabilitesCVKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

  • CVKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.91%.
EPS 1Y (TTM)-19.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CVKD will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.00% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.27%
EPS Next 2Y26.61%
EPS Next 3Y16.04%
EPS Next 5Y13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CVKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVKD Price Earnings VS Forward Price EarningsCVKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVKD Per share dataCVKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • CVKD's earnings are expected to grow with 16.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.61%
EPS Next 3Y16.04%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CVKD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (1/14/2026, 10:02:59 AM)

8.75

+0.08 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-11
Inst Owners8.34%
Inst Owner Change0%
Ins Owners12.24%
Ins Owner Change-6.16%
Market Cap18.20M
Revenue(TTM)N/A
Net Income(TTM)-14.39M
Analysts82.86
Price Target36.38 (315.77%)
Short Float %4%
Short Ratio1.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.53%
Min EPS beat(2)-14.82%
Max EPS beat(2)15.87%
EPS beat(4)1
Avg EPS beat(4)-20.17%
Min EPS beat(4)-56.79%
Max EPS beat(4)15.87%
EPS beat(8)2
Avg EPS beat(8)-20.29%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.36%
EPS NQ rev (1m)14.7%
EPS NQ rev (3m)34.81%
EPS NY rev (1m)0%
EPS NY rev (3m)3.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.65
P/tB 6.65
EV/EBITDA N/A
EPS(TTM)-8.01
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-5.68
FCFYN/A
OCF(TTM)-5.68
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -351.94%
ROE -525.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 3.02
Altman-Z -15.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.91%
EPS Next Y20.27%
EPS Next 2Y26.61%
EPS Next 3Y16.04%
EPS Next 5Y13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-84.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.85%
EBIT Next 3Y-47.56%
EBIT Next 5Y-40.95%
FCF growth 1Y-108.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.41%
OCF growth 3YN/A
OCF growth 5YN/A

CADRENAL THERAPEUTICS INC / CVKD FAQ

What is the ChartMill fundamental rating of CADRENAL THERAPEUTICS INC (CVKD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CVKD.


What is the valuation status of CADRENAL THERAPEUTICS INC (CVKD) stock?

ChartMill assigns a valuation rating of 0 / 10 to CADRENAL THERAPEUTICS INC (CVKD). This can be considered as Overvalued.


Can you provide the profitability details for CADRENAL THERAPEUTICS INC?

CADRENAL THERAPEUTICS INC (CVKD) has a profitability rating of 0 / 10.


Can you provide the financial health for CVKD stock?

The financial health rating of CADRENAL THERAPEUTICS INC (CVKD) is 6 / 10.